Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734591 · ClinicalTrials.gov registry record
Follow-Up Study for Exubera
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 7,439
- Enrollment target
NCT00734591 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 7,439 participants.
The verdict
NCT00734591 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 7,439 participants
- Enrollment target
Study Summary
In studies of Exubera in persons with diabetes, lung cancer occurred in a few more people who were taking Exubera than in people who were taking other diabetes medicines. All subjects diagnosed with lung cancer had a history of smoking and the number of lung cancer cases observed fell within the expected range based on population-based data. There is currently not enough information to determine if any of the observed lung cancer cases were related to Exubera use, therefore, the study is being conducted to further investigate whether Exubera use makes the appearance of lung cancer more likely.
Interventions
- DRUG Exubera
- OTHER Randomized diabetes therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,439 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00734591
The ClinicalTrials.gov registry entry for NCT00734591 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7,439 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exubera is the first listed.
NCT00734591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00734591 about?
NCT00734591 is a clinical study titled "Follow-Up Study for Exubera". In studies of Exubera in persons with diabetes, lung cancer occurred in a few more people who were taking Exubera than in people who were taking other diabetes medicines. All subjects diagnosed with lung cancer had a history of smoking and the number of lung cancer cases observed fell within the exp...
What is the current status of trial NCT00734591?
This trial is currently completed. The enrollment target is 7,439 participants. The study started on 2008-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00734591?
The interventions under investigation include: Exubera (DRUG), Randomized diabetes therapy (OTHER).
Who is sponsoring clinical trial NCT00734591?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.